IPO Details

About Company

Sahajanand Medical Technologies Ltd. (SMT) is a prominent player in the Indian medical device industry, incorporated in 2004. The company specializes in the manufacturing of cardiovascular medical devices, particularly focusing on stents and other interventional cardiology products. SMT operates under the umbrella of the Sahajanand Group, which has a diverse portfolio in healthcare and technology. The company boasts a robust product portfolio that includes drug-eluting stents, balloon catheters, and peripheral vascular products, catering to a wide range of cardiovascular conditions. With state-of-the-art manufacturing facilities located in Surat, Gujarat, SMT has established significant production capacities that adhere to international quality standards. Geographically, the company has a strong presence not only in India but also in international markets, exporting to over 50 countries. Its distribution network is extensive, leveraging partnerships with hospitals and healthcare providers to ensure the availability of its products. As of the latest financials, SMT reported a total income of INR 500 crores, a net profit of INR 80 crores, an EBITDA margin of 25%, a return on capital employed (ROCE) of 15%, a return on equity (ROE) of 12%, and a debt-equity ratio of 0.5. The IPO aims to raise funds for expanding manufacturing capacities, enhancing R&D efforts, and reducing existing debt. Post-issue, the market capitalization is expected to be around INR 3,000 crores, with an earnings per share (EPS) of INR 10 and a price-to-earnings (P/E) ratio of 30. Investor sentiment appears to be positive, driven by the growing demand for medical devices and the company's strategic growth initiatives.